Business Description
Cognition Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US19243B1026
Total Employee Number:
14Description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 66.95 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 29.1 | |||||
3-Year EPS without NRI Growth Rate | 29.4 | |||||
3-Year FCF Growth Rate | 24.7 | |||||
3-Year Book Growth Rate | -34.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.38 | |||||
9-Day RSI | 33.23 | |||||
14-Day RSI | 37.54 | |||||
3-1 Month Momentum % | -20.31 | |||||
6-1 Month Momentum % | -28.67 | |||||
12-1 Month Momentum % | 18.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.92 | |||||
Quick Ratio | 5.92 | |||||
Cash Ratio | 5.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.3 | |||||
Shareholder Yield % | -42.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -81.56 | |||||
ROA % | -57.23 | |||||
ROIC % | -715.4 | |||||
3-Year ROIIC % | 91.18 | |||||
ROC (Joel Greenblatt) % | -4002.45 | |||||
ROCE % | -80.77 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.74 | |||||
Price-to-Tangible-Book | 2.7 | |||||
EV-to-EBIT | -2.64 | |||||
EV-to-Forward-EBIT | -1.3 | |||||
EV-to-EBITDA | -2.67 | |||||
EV-to-FCF | -2.55 | |||||
| Price-to-Net-Current-Asset-Value | 2.78 | |||||
| Price-to-Net-Cash | 3.28 | |||||
Earnings Yield (Greenblatt) % | -37.88 | |||||
FCF Yield % | -24.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cognition Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.24 | ||
| Beta | 1.8118 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 1.45 | ||
| Volatility % | 337.8 | ||
| 14-Day RSI | 37.54 | ||
| 14-Day ATR ($) | 0.101886 | ||
| 20-Day SMA ($) | 1.036475 | ||
| 12-1 Month Momentum % | 18.38 | ||
| 52-Week Range ($) | 0.5501 - 3.83 | ||
| Shares Outstanding (Mil) | 89.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cognition Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cognition Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 104 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 13 days | ||
| General meeting for 2026 | 2026-06-17 09:00 | 1.26 (+3.28%) | ||
| H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 2026-06-15 | 1.21 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 13:25 | 1.42 (+5.97%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 1.16 (-6.45%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 15:00 | 0.90 (-0.48%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 08:30 | 1.11 (-3.48%) | ||
| Annual report for 2025 | 2026-03-26 | 1.11 (-3.48%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 1.11 (-3.48%) |
Show
Entries
Cognition Therapeutics Inc Frequently Asked Questions
What is Cognition Therapeutics Inc(CGTX)'s stock price today?
The current price of CGTX is $0.92. The 52 week high of CGTX is $3.83 and 52 week low is $0.55.
When is next earnings date of Cognition Therapeutics Inc(CGTX)?
The next earnings date of Cognition Therapeutics Inc(CGTX) is 2026-08-07 Est..
Does Cognition Therapeutics Inc(CGTX) pay dividends? If so, how much?
Cognition Therapeutics Inc(CGTX) does not pay dividend.
Guru Commentaries on NAS:CGTX
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Pittsburgh Life Sciences Greenhouse Proudly Announces IPO of Portfolio Company Cognition Therapeutics | 2021-10-12 |
Articles on Cognition Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers